AI Article Synopsis
- The review assesses the effects of curcumin as a treatment for cancer, noting that while preclinical studies are abundant, human trials show mixed results.
- Only seven out of 114 studies were suitable for analysis, focusing on various cancers and using curcumin mainly as an additional treatment.
- Although curcumin showed some positive effects on cancer response, it did not significantly improve overall survival or progression-free survival, suggesting that further research is needed to better understand its potential benefits in early-stage cancers.
Article Abstract
Although the anticancer role of curcumin has been extensively addressed in preclinical research, only a few studies were carried out in humans, with conflicting results. The aim of this systematic review is to collate together the results of the therapeutic effect of curcumin in cancer patients. A literature search was carried out in Pubmed, Scopus, and the Cochrane Central Register of Controlled Trials up to 29 January 2023. Only randomized controlled trials (RCTs) designed to evaluate the effects of curcumin on cancer progression, patient survival, or surgical/histological response were included. Seven out of 114 articles, published between 2016 and 2022, were analyzed. They evaluated patients with locally advanced and/or metastatic prostate, colorectal, and breast cancers, as well as multiple myeloma and oral leucoplakia. Curcumin was given as an add-on therapy in five studies. Cancer response was the most investigated primary endpoint and curcumin issued some positive results. On the contrary, curcumin was ineffective in improving overall or progression-free survival. The curcumin safety profile was favorable. In conclusion, available clinical evidence is not strong enough to support the therapeutic use of curcumin in cancer. New RCTs exploring the effects of different curcumin formulations in early-stage cancers would be welcome.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144810 | PMC |
| http://dx.doi.org/10.3390/pharmaceutics15041275 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ferrocenyl-Substituted Curcumin Derivatives as Potential SHP-2 Inhibitors for Anticolorectal Cancer: Design, Synthesis and Evaluation.
ACS Omega
December 2024
Tianjin Key Laboratory of Therapeutic Substance of Traditional Chinese Medicine, School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, P. R. China.
A panel of ferrocenyl-substituted curcumin derivatives has been designed and synthesized as protein tyrosine phosphatase proto-oncogene SHP-2 inhibitors. Antiproliferative activities of the synthesized compounds were tested against colorectal cancer cell lines (including RKO, SW480, and CT26). Compound showed excellent activities against the tested cell lines with IC values of 5.
View Article and Find Full Text PDFInvestigating the effect of femtosecond laser pulses on noscapine and curcumin cellular uptake and improving drug delivery in gastric cancer cells.
Heliyon
January 2025
Laser and Plasma Research Institute, Shahid Beheshti University, Tehran, Iran.
The MKN45 cell line, a type of gastric cancer cell, exhibits resistance to chemotherapy agents through various mechanisms. Curcumin and noscapine, two plant-derived anticancer compounds, exhibit selective cytotoxicity towards cancer cells. However, their bioavailability is poor both in vitro and in vivo.
View Article and Find Full Text PDFRecent Prospectives of Cellular Signaling Role for Mammary Gland Carcinogenesis.
Anticancer Agents Med Chem
January 2025
Department of Pharmaceutical Sciences, Lucknow University, Lucknow, UP, India.
In women globally, breast cancer ranks as the second most frequent cause of cancer-related deaths, making up about 25% of female cancer cases, which is pretty standard in affluent countries. Breast cancer is divided into subtypes based on aggressive, genetic and stage. The precise cause of the problem is still unknown.
View Article and Find Full Text PDFSynergistic Anticancer Efficacy of Curcumin and Doxorubicin Combination Treatment Inducing S-phase Cell Cycle Arrest in Triple-Negative Breast Cancer Cells: An In Vitro Study.
Cureus
December 2024
Department of Biochemistry, Era's Lucknow Medical College and Hospital, Era University, Lucknow, IND.
Background: Curcumin (Cur) is a polyphenol phyto-compound found in turmeric () that inhibits tumorigenesis by introducing apoptosis and restricting cell survival and proliferation. This in vitro research article focuses on the pharmacodynamic interactions of Cur combined with the commercial drug doxorubicin (Doxo) to enhance the cytotoxicity of Doxo at lower doses against triple-negative breast cancer cells (MDA-MB-231) with the chemo-protective effect against normal HEK293 cells. In this study, we observed the dose-dependent cytotoxicity, increased reactive oxygen species (ROS) generation, and increased chromatin condensation in combination doses compared to single doses.
View Article and Find Full Text PDFThe anticancer activity of fucoidan coated selenium nanoparticles and curcumin nanoparticles against colorectal cancer lines.
Sci Rep
January 2025
Department of Fish Processing and Biotechnology, Faculty of Aquatic and Fisheries Sciences, Kafrelsheikh University, Kafrelsheikh, 33516, Egypt.
Cancers still globally endanger millions of people yearly; the incidences/mortalities of colorectal cancers are particularly increasing. The natural nanoparticles (NPs) and marine biopolymers were anticipated to provide effectual safe significances for managing cancers. The transformation of curcumin to nano-curcumin (NCur) was conducted with gum Arabic.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!